Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 2/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199069 | 0.81 | TGM2 (0.31) | TGM2CES1HTR2CBRD4AHR | |
| SCHEMBL3910092 | 0.79 | BRD4 (0.37) | TGM2CES1BRD4AHRCMA1 | |
| SCHEMBL2194416 | 0.76 | KDM4E (0.32) | CA12CA2CA9 | |
| SCHEMBL30695309 | 0.76 | HTR5A (0.33) | HTR2CAHRPARP10PARP1 | |
| SCHEMBL1257327 | 0.76 | AHR (0.35) | TGM2CES1HTR2CAHRCMA1 | |
| SCHEMBL8469855 | 0.76 | ALDH1A1 (0.34) | PARP10PARP11PARP1 | |
| SCHEMBL9453911 | 0.76 | DRD2 (0.41) | CA12CA2CA9 | |
| SCHEMBL3503657 | 0.73 | CYP2A6 (0.38) | — | |
| SCHEMBL4366398 | 0.72 | PDE3B (0.41) | CA12CA2CA9 | |
| SCHEMBL3503655 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865883-A | Preparation method of 6-bromoquinoline | 常州琦诺生物科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20180002295-A1 | Compositions and Methods for Treating Anxiety and Compulsive Behavior | UNIV IOWA RES FOUND (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2016118952-A1 | COMPOSITIONS AND METHODS FOR TREATING ANXIETY AND COMPULSIVE BEHAVIOR | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20070265449-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-7166726-B2 | Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20030130515-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| EP-0948478-B1 | ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6087505-A | Benzo[1,2-G]-chrom-3-ene, and benzo[1,2-G]-thiochrom-3-ene derivatives | ALLERGAN SALES, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| US-5728846-A | RETENOIDS, RETINOID ACTIVITY; AGONISTS, ANTAGONISTS | ALLERGAN (US) | 1998-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265449-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | RXRG, RARG, NR2E3 | TGM2 1251/4885CES1 1047/4885HTR2C 323/4885 |
| US-20030130515-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | RXRG, NR2E3, RARG | TGM2 1306/4885CES1 709/4885HTR2C 360/4885 |
| US-20180002295-A1 | Compositions and Methods for Treating Anxiety and Compulsive Behavior | HCRTR1, CHAT, CRH | TGM2 1180/4885CES1 2385/4885HTR2C 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.